病的近視に伴う脈絡膜新生血管（mCNV）におけるVEGFトラップアイ

基本情報

NCT ID

NCT01249664

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

122

治験依頼者名

Bayer

概要

VEGF Trap-Eye will be tested for safety and efficacy in patients with vision loss due to choroidal neovascularization secondary to pathologic myopia. This will be a placebo-controlled trial. 3 out of 4 patients will receive an injection of VEGF Trap-Eye into the affected eye (and repeated injections if required), and 1 out of 4 patients will receive a sham injection requiring no needle stick, but making the patient unaware of whether or not he received active treatment. Outcome of the two treatment groups will be compared after 24 weeks. From week 24, sham patients may receive active treatment. Total duration of the study will be 48 weeks.

対象疾患

介入

依頼者（Sponsor）